KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) EBT (2016 - 2025)

Gilead Sciences (GILD) has disclosed EBT for 17 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 4.11% year-over-year to $2.1 billion, compared with a TTM value of $9.8 billion through Dec 2025, up 1319.71%, and an annual FY2025 reading of $9.8 billion, up 1319.71% over the prior year.
  • EBT was $2.1 billion for Q4 2025 at Gilead Sciences, down from $3.6 billion in the prior quarter.
  • Across five years, EBT topped out at $3.6 billion in Q3 2025 and bottomed at -$4.5 billion in Q1 2024.
  • Average EBT over 5 years is $1.6 billion, with a median of $1.9 billion recorded in 2021.
  • The sharpest move saw EBT soared 955.26% in 2023, then plummeted 445.08% in 2024.
  • Year by year, EBT stood at $759.0 million in 2021, then surged by 167.59% to $2.0 billion in 2022, then dropped by 18.61% to $1.7 billion in 2023, then surged by 31.09% to $2.2 billion in 2024, then fell by 4.11% to $2.1 billion in 2025.
  • Business Quant data shows EBT for GILD at $2.1 billion in Q4 2025, $3.6 billion in Q3 2025, and $2.4 billion in Q2 2025.